Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Maze Therapeutics (MAZE) Shares Outstanding (2024 - 2025)

Maze Therapeutics has reported Shares Outstanding over the past 2 years, most recently at $49.3 million for Q4 2025.

  • Quarterly Shares Outstanding rose 1916.28% to $49.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.3 million through Dec 2025, up 1916.28% year-over-year, with the annual reading at $49.3 million for FY2025, 1916.28% up from the prior year.
  • Shares Outstanding was $49.3 million for Q4 2025 at Maze Therapeutics, up from $48.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $49.3 million in Q4 2025 and troughed at $2.4 million in Q1 2024.